New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it

Lipids Health Dis. 2017 Apr 4;16(1):70. doi: 10.1186/s12944-017-0462-1.

Abstract

Background: Bone morphogenetic protein 4 (BMP-4) has been proven to regulate white adipogensis. We aimed to demonstrate the correlation of BMP-4 with fat distribution and Exenatide treatment on it.

Methods: We enrolled 69 obese patients. Anthropometric and metabolic indexes were collected. Fat distribution was measured by dual-energy X-ray absorptiometry. BPM-4 levels were assessed using enzyme-link immunosorbent assay kit. 30 obese patients were treated with Exenatide twice a day. Change in body weight, metabolic-related indices and BPM-4 levels were evaluated after 18 weeks.

Results: 1) The mean(±SD) BMP-4 levels were 763.98 ± 324.11 pg/ml in the obese. BPM-4 levels were significantly positively correlated with estimated visceral adipose tissue mass in all subjects and also in females (r = 0.377, r = 0.625, respectively,all P < 0.05). BPM-4 levels were also significantly positively correlated with body mass index, hip circumference and total fat% in females (r = 0.375,r = 0.429,r = 0.493,respectively, all P < 0.05). BPM-4 levels were negatively correlated with total cholesterol(TC) in all subjects and males also (r = -0.373,r = -0.332,respectively, all P < 0.05). BPM-4 levels were also significantly positively correlated with free triiodothyronine in males (r = 0.441, P < 0.05). 3) Multivariate analyses showed that TC was risk factor of BMP-4 concentration in males and Est.VAT Area was risk factor of BMP-4 levels in females. 4) BMP-4 levels were significantly higher in the obesity with slightly increased thyroid stimulating hormone(TSH) than the obesity without slightly increased TSH (902.08 ± 354.74 pg/ml vs. 720.24 ± 306.41 pg/ml, P < 0.05). 5) Exenatide treatment leads to a significant decreased in BMP-4 from 860.05 ± 352.65 pg/ml to 649.44 + 277.49 pg/ml independent of weight loss(P < 0.05).

Conclusion: BMP-4 levels were associated with the visceral adipose tissue and may play a certain role in fat distribution and subclinical hypothyroidism in obesity. Exenatide treatment reduced BMP-4 levels independent of weight loss.

Trial registration: Clinicaltrials.gov Identifier: NCT02118376 , Registered 16 April.

Keywords: Bone morphogenetic protein 4; Exenatide; Fat distribution; Obesity.

Publication types

  • Clinical Trial

MeSH terms

  • Absorptiometry, Photon
  • Adiposity / drug effects*
  • Adult
  • Body Mass Index
  • Bone Morphogenetic Protein 4 / antagonists & inhibitors
  • Bone Morphogenetic Protein 4 / blood*
  • China
  • Cholesterol / blood
  • Drug Monitoring
  • Exenatide
  • Female
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Humans
  • Incretins / administration & dosage
  • Incretins / therapeutic use*
  • Intra-Abdominal Fat / diagnostic imaging
  • Intra-Abdominal Fat / drug effects*
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / diagnostic imaging
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Reproducibility of Results
  • Sex Characteristics
  • Thyrotropin / blood
  • Triiodothyronine / blood
  • Venoms / administration & dosage
  • Venoms / therapeutic use*
  • Weight Loss / drug effects

Substances

  • BMP4 protein, human
  • Bone Morphogenetic Protein 4
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Incretins
  • Peptides
  • Venoms
  • Triiodothyronine
  • Thyrotropin
  • Cholesterol
  • Exenatide

Associated data

  • ClinicalTrials.gov/NCT02118376